Drug Approval | April 15, 2022
Lupin receives approval from USFDA for Desvenlafaxine extended-release tablets 25 mg
The product will be manufactured at Lupin’s facility in Goa, India
The product will be manufactured at Lupin’s facility in Goa, India
Under the agreement, Univar Solutions customers in Brazil and Mexico will have access to Ashland's binders and disintegrants for solid dosage forms, matrix formers for modulated release drugs and coatings for regular and modulated release solid dosage forms
The joint partnership, powered by Cloudbyz Clinical Research Management Platform and ClinChoice's industry-leading transformation services, will provide an end-to-end clinical research management technology platform and services to customers
The DRX-Compass helps navigate and accelerate towards superb performance with a solution that grows with its customers
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Merzee is a generic equivalent of Taytulla of Allergan Pharmaceuticals International
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
The new facility is scheduled to start operation in the first half of 2024
Subscribe To Our Newsletter & Stay Updated
